Using a policy simulation model and the concept of decremental cost-effectiveness analysis,14,15 this paper aims to quantify what level of savings society would be willing to accept (ie, lower spending on GLP-1/IM drugs) to potentially forgo the health benefits (eg, maintenance of weight loss, improvements in cardiometabolic risk factors, and reductions in diabetes and cardiovascular events) to expand GLP-1/IM access to more people during the weight-loss phase. The gene discussed is GCG; the disease is diabetes mellitus.